CLO-Northwestern University A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 By Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer Cancer Prevention and Control CIRB Active Available to Open